Dysregulation of alternative splicing has been implicated in the pathogenesis of various diseases, including cancer, as it can lead to aberrant protein isoforms that may have oncogenic properties or result in the loss of tumor suppressor activity (Kahles et al. 2018), for e.g. roles of alternative splicing of the CD44 and BCL2L1 genes in various types of cancer (Brown et al. 2011, Jiang et al. 2014). This evidence concerns the gene BCL2L1 and cancer.